Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study

A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the study and a press release issued by daratumumab manufacturers Genmab and Johnson & Johnson, the data showed a 36% response rate in the group treated in phase two of the study and furthermore, 65% of those patients had not experienced disease progression in the 12 months after the start of treatment.

Source: International Myeloma Foundation - August 28, 2015 Category: Hematology Source Type: news